Literature DB >> 11050265

Development of a disease specific health related quality of life measure for adults and adolescents with cystic fibrosis.

L Gee1, J Abbott, S P Conway, C Etherington, A K Webb.   

Abstract

BACKGROUND: Health related quality of life (HRQoL) measurement is important in determining the impact of disease on daily functioning and subsequently informing interventions. In cystic fibrosis (CF) generic HRQoL measures have been employed but these may not be sufficiently specific. The aim of the current work was to develop and validate a disease specific HRQoL measure for adults and adolescents with cystic fibrosis.
METHODS: Areas of concern to adults and adolescents with CF were identified by unstructured interviews, self-administered questionnaires, consultation with multidisciplinary specialist staff, a review of the relevant literature, and examination of other HRQoL measures. Items for the questionnaire were generated on the basis of this process. Continued evaluation and development of the Cystic Fibrosis Quality of Life (CFQoL) questionnaire was undertaken by a process of statistical analysis and continued feedback from patients. The full testing and validation of the CFQoL questionnaire took place over four phases: (1) initial item generation and testing of a preliminary questionnaire, (2) testing and validation of the second version of the questionnaire, (3) test-retest reliability of a third and final version of the questionnaire, and (4) sensitivity testing of the final version of the questionnaire.
RESULTS: Nine domains of functioning were identified using principal components analysis with varimax rotation. Internal reliability of the identified domains was demonstrated using Cronbach alpha coefficients (range 0.72-0.92) and item to total domain score correlations. Concurrent validity (range r = 0.64-0.74), discriminatory ability between different levels of disease severity, sensitivity across transient changes in health (effect size range, moderate d = 0.56 to large d = 1.95), and test-retest reliability (r = 0.74-0.96) were also found to be robust.
CONCLUSIONS: The CFQoL questionnaire is a fully validated disease specific measure consisting of 52 items across nine domains of functioning which have been identified by, and are of importance to, adolescents and adults with cystic fibrosis. This measure will be useful in clinical trials and longitudinal studies.

Entities:  

Mesh:

Year:  2000        PMID: 11050265      PMCID: PMC1745639          DOI: 10.1136/thorax.55.11.946

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  17 in total

Review 1.  A two way view of gender bias in medicine.

Authors:  M T Ruiz; L M Verbrugge
Journal:  J Epidemiol Community Health       Date:  1997-04       Impact factor: 3.710

2.  Evidence for the sensitivity of the SF-36 health status measure to inequalities in health: results from the Oxford healthy lifestyles survey.

Authors:  C Jenkinson; R Layte; A Coulter; L Wright
Journal:  J Epidemiol Community Health       Date:  1996-06       Impact factor: 3.710

3.  Gender and cross-cultural differences in somatic symptoms associated with emotional distress. An international study in primary care.

Authors:  M Piccinelli; G Simon
Journal:  Psychol Med       Date:  1997-03       Impact factor: 7.723

4.  Measurement of general health status of non-oxygen-dependent chronic obstructive pulmonary disease patients.

Authors:  J Alonso; J M Antó; M González; J A Fiz; J Izquierdo; J Morera
Journal:  Med Care       Date:  1992-05       Impact factor: 2.983

5.  Measuring the quality of life before and after bilateral lung transplantation in patients with cystic fibrosis.

Authors:  J J Busschbach; P E Horikx; J M van den Bosch; A Brutel de la Rivière; F T de Charro
Journal:  Chest       Date:  1994-03       Impact factor: 9.410

6.  Gender differences in the comparison of self-reported disability and performance measures.

Authors:  S S Merrill; T E Seeman; S V Kasl; L F Berkman
Journal:  J Gerontol A Biol Sci Med Sci       Date:  1997-01       Impact factor: 6.053

Review 7.  Gender variations in clinical pain experience.

Authors:  A M Unruh
Journal:  Pain       Date:  1996 May-Jun       Impact factor: 6.961

8.  Validating the SF-36 health survey questionnaire: new outcome measure for primary care.

Authors:  J E Brazier; R Harper; N M Jones; A O'Cathain; K J Thomas; T Usherwood; L Westlake
Journal:  BMJ       Date:  1992-07-18

9.  The SF36 health survey questionnaire: an outcome measure suitable for routine use within the NHS?

Authors:  A M Garratt; D A Ruta; M I Abdalla; J K Buckingham; I T Russell
Journal:  BMJ       Date:  1993-05-29

10.  The effect of chronic obstructive pulmonary disease on quality of life.

Authors:  K L Anderson
Journal:  Res Nurs Health       Date:  1995-12       Impact factor: 2.228

View more
  63 in total

1.  Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis.

Authors:  Valerie Waters; Felix Ratjen
Journal:  Cochrane Database Syst Rev       Date:  2020-06-10

2.  Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.

Authors:  Sherie Smith; Valerie Waters; Nikki Jahnke; Felix Ratjen
Journal:  Cochrane Database Syst Rev       Date:  2020-06-10

Review 3.  Vitamin K supplementation for cystic fibrosis.

Authors:  Vanitha A Jagannath; Zbys Fedorowicz; Vidhu Thaker; Anne B Chang
Journal:  Cochrane Database Syst Rev       Date:  2015-01-18

Review 4.  How a clinical psychologist manages the problems of adults with cystic fibrosis.

Authors:  Helen Oxley; A K Webb
Journal:  J R Soc Med       Date:  2005       Impact factor: 5.344

Review 5.  Vitamin E supplementation in people with cystic fibrosis.

Authors:  Peter O Okebukola; Sonal Kansra; Joanne Barrett
Journal:  Cochrane Database Syst Rev       Date:  2017-03-06

6.  Self-reported physical and psychological symptom burden in adults with cystic fibrosis.

Authors:  Gregory S Sawicki; Deborah E Sellers; Walter M Robinson
Journal:  J Pain Symptom Manage       Date:  2008-01-22       Impact factor: 3.612

7.  Validity and Reliability of a Novel Multimodal Questionnaire for the Assessment of Abdominal Symptoms in People with Cystic Fibrosis (CFAbd-Score).

Authors:  Anke Jaudszus; Elisa Zeman; Tatjana Jans; Elena Pfeifer; Harold Tabori; Christin Arnold; Ruth K Michl; Michael Lorenz; Natalie Beiersdorf; Jochen G Mainz
Journal:  Patient       Date:  2019-08       Impact factor: 3.883

8.  The Caregiver Quality of Life Cystic Fibrosis (CQOLCF) scale: modification and validation of an instrument to measure quality of life in cystic fibrosis family caregivers.

Authors:  Whitney Boling; David M Macrina; John P Clancy
Journal:  Qual Life Res       Date:  2003-12       Impact factor: 4.147

Review 9.  Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy.

Authors:  Edith T Zemanick; J Kirk Harris; Steven Conway; Michael W Konstan; Bruce Marshall; Alexandra L Quittner; George Retsch-Bogart; Lisa Saiman; Frank J Accurso
Journal:  J Cyst Fibros       Date:  2009-10-14       Impact factor: 5.482

10.  Health-related quality of life in children with cystic fibrosis: validation of the German CFQ-R.

Authors:  Anne Schmidt; Kerstin Wenninger; Nadja Niemann; Ulrich Wahn; Doris Staab
Journal:  Health Qual Life Outcomes       Date:  2009-12-02       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.